

ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

Therapeutic effect of mesotherapy on pain in patients with knee osteoarthritis

Maša Jakšić^{1,2}, Ivana Ilić^{1,2}, Saša Milićević^{1,2}, Dušan Petrović^{1,2}, Saša Jovanović^{1,2}, Andrijana Spasojević¹, Nataša Macut Đukić², Lazar Popivoda¹, Nikola Mihajlović¹

¹Clinical Hospital Center in Kosovska Mitrovica, Kosovska Mitrovica, Serbia;

²University in Priština – Kosovska Mitrovica, Faculty of Medicine, Kosovska Mitrovica, Serbia



SUMMARY

Introduction/Objective Knee osteoarthritis is a progressive, degenerative disease of the knee joint that can eventually lead to disability. Clinical mesotherapy is an intradermal therapy used for injecting diluted pharmacological substances into the superficial layer of the skin at multiple points. The objectives of this study were to determine the therapeutic effect of mesotherapy on pain in patients with knee osteoarthritis treated with a mixture of Zodol (Zodol, 30 mg/mL, Hemofarm, Vršac, Serbia) and lidocaine, compared to patients with knee osteoarthritis treated with lidocaine alone.

Methods Participants were randomly assigned into two groups. The experimental group, in which patients were treated with an injection containing a mixture of lidocaine without adrenaline (Lidocainechlorid 1%, 35 mg / 3.5 mL, Galenika, Belgrade, Serbia) and of Zodol (Hemofarm). The control group was treated with lidocaine solution without adrenaline.

Results There is a statistically significant difference in pain intensity after the second dose of mesotherapy and one month after the fourth dose of mesotherapy. Western Ontario and McMaster Universities Osteoarthritis Index scale values were significantly higher in patients in the control group. The frequency of patients experiencing moderate and severe pain was significantly higher in the control group, while the frequency of patients reporting no pain or only mild pain was significantly higher in the experimental group.

Conclusion The therapeutic effect of mesotherapy on pain in patients with knee osteoarthritis in experimental group is more effective and longer-lasting compared to patients treated with lidocaine alone.

Keywords: mesotherapy on pain; knee osteoarthritis; intradermal therapy

INTRODUCTION

Knee osteoarthritis is a degenerative joint disease that occurs as a result of progressive loss of articular cartilage. It most commonly affects older adults. It can be divided into two types: primary and secondary. Primary osteoarthritis occurs without any apparent cause, while secondary osteoarthritis can result from other conditions, most commonly including post-traumatic and post-surgical states, rickets, gout, and others. Common clinical symptoms include knee pain, which develops gradually and worsens with activity, as well as stiffness and swelling of the knee. Treatment of knee osteoarthritis begins with conservative methods, and if these do not yield results, surgical treatment is considered [1]. Nonsteroidal anti-inflammatory drugs (NSAID) are the first line of treatment for knee osteoarthritis. However, patients who cannot take these medications or do not respond to them may try intra-articular corticosteroid injections, which usually relieve pain for several weeks. When it comes to non-pharmacological treatment, patient education, weight loss (for those who are overweight), and exercise play important roles. Exercises usually focus on strengthening the muscles of the lower limbs, which helps reduce pain and improve functional status [2].

Clinical mesotherapy

Therapeutic skin injections date back to ancient Chinese and Indian medicine. In 1958, Michel Pistor introduced the term “mesotherapy” to describe the inoculation of drugs into the superficial layer of the skin [3].

Clinical mesotherapy is an intradermal therapy used to inject diluted pharmacological substances into the superficial layer of the skin at multiple points, at a depth of 3–4 mm. Specifically, this involves the use of a short needle to deposit the drug into the dermis. The intradermal microdeposit modulates the drug's kinetics by slowing absorption and prolonging the local mechanism of action [3, 4, 5]. This technique involves infiltrating a small amount of the drug into the superficial layer of the skin, observing the painful area. When injected intradermally, the drug diffuses into the tissues and joints, remaining for a longer period than with intramuscular administration. The goal of mesotherapy is to achieve the therapeutic benefit with lower drug doses when other options have failed, cannot be used, or are unavailable [6]. Many localized pain syndromes benefit from mesotherapy; in fact, mesotherapy is used to treat localized pain, resulting in improved quality of life [7]. Mesotherapy on pain is a safe method and has no adverse effects [4].

Received • Примљено:
November 19, 2025

Revised • Ревизија:
March 15, 2026

Accepted • Прихваћено:
March 25, 2026

Online first: April 9, 2026

Correspondence to:

Maša JAKŠIĆ
University in Priština – Kosovska
Mitrovica
Faculty of Medicine
Anri Dinana bb
38220 Kosovska Mitrovica
Serbia
masamalikovic@yahoo.com

The mesotherapy technique involves the inoculation of the drug using a 4 mm (27G) or 13 mm (30–32G) needle. The angle of the needle depends on the area being treated. The technique requires medical and pharmacological knowledge and must be performed in accordance with disinfection protocols (appropriate disinfectants are necessary) using sterile single-use devices [3]. It should be noted that despite the widespread use of mesotherapy, certain uncertainties still exist, and further preclinical and clinical research is needed to define its role in clinical practice [6]. Although it has a wide range of applications, there is still no standardized protocol. For these reasons, every study conducted in the field of mesotherapy is highly valuable [8].

METHODS

The study was designed as a prospective randomized, double-blind study and was conducted at the Clinical Hospital Center Kosovska Mitrovica, in the Department of Physical Medicine and Rehabilitation, over a period of eight weeks. The randomization code was generated using a computer-generated random number sequence, where participants were assigned in two groups in 1:1 ratio. The randomization list was prepared by an independent person not involved in participant selection. A total of 59 patients were included in the study – 16 male and 43 female patients. Although a formal statistical power analysis was not conducted prior to the start of research, the number of participants was sufficient to perform the planned statistical analysis and to monitor changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analogue scale (VAS) at defined time points. The experimental group consisted of 31 patients, while the control group included 28 patients. The average age of patients in the experimental group was 58.7 ± 14.5 years, and in the control group 60.3 ± 15 years. The study was conducted after obtaining written informed consent from all participants. All patients were diagnosed with knee osteoarthritis prior to the study. During medical history taking, attention was paid to possible allergic reactions to the medication and the use of anticoagulant therapy, which are absolute contraindications for performing this procedure. Pain was assessed using VAS – before the start of the study, after the second dose, and one month after the fourth dose. Functional status was assessed using the WOMAC scale – at the beginning of the study, after the second dose, and one month after the fourth dose. VAS is a tool used to measure pain intensity. The scale is typically a 10-centimeter (or 100-millimeter) line marked from 0 to 10 or 0 to 100. The far-left point represents no pain (0), while the far-right point represents unbearable pain (10 or 100). Patients mark the point on the line that corresponds to their current pain intensity. The WOMAC is a questionnaire used to measure osteoarthritis symptoms in patients with knee or hip osteoarthritis. The scale covers three domains: pain, stiffness, and functional limitations. Results are measured on a Likert scale from 0 to 4, where zero

indicates “none” and four indicates “extreme” symptoms. Higher scores indicate greater levels of pain, stiffness, and functional impairment.

A detailed medical history was taken from all patients, followed by a clinical examination and knee radiography. Participants were randomly assigned into two groups. The first was the experimental group, in which patients were treated with an injection containing a mixture of 1 mL of 1% lidocaine without adrenaline (Lidocainechlorid 1%, 35 mg / 3.5 mL, Galenika, Belgrade, Serbia) and 1 mL of Zodal (Zodal, 30 mg/mL, Hemofarm, Vršac, Serbia). The control group was treated with 1 mL of a Lidocaine solution without adrenaline. The mesotherapy protocol involved the use of sterile, single-use 2.5 mL syringes with a $30G \times 4$ mm needle, inserted at a 90° angle against the skin. Each patient received injections once a week, for a total of four doses, with the fourth dose administered one month after the third. Patients were treated using the “point-by-point” technique, targeting painful areas around the knee.

Before enrolment in the study and initiation of mesotherapy for pain management, participants were fully informed about the study protocol and declared that NSAID therapy has been discontinued at least 10 days prior to treatment and that no medications from this group were used through the duration of the study.

Descriptive methods and statistical hypothesis testing methods were used for the analysis of primary data. Among the descriptive statistical methods, measures of central tendency (arithmetic mean and median), measures of variability (standard deviation and range), and relative numbers were applied. For hypothesis testing, the Mann–Whitney test and the Friedman test were used. Statistical analysis was performed using the IBM SPSS Statistics for Windows, Version 21.0. (IBM Corp., Armonk, NY, USA). Statistical hypotheses were tested at a significance level of 0.05.

Ethics: The approval for conducting this study was obtained from the Ethics Committee of the Health Center in Kosovska Mitrovica.

RESULTS

A total of 59 patients were included in the study – 16 male and 43 female patients. The experimental group consisted of 31 patients, while the control group included 28 patients. The average age of patients in the experimental group was 58.7 ± 14.5 years, and in the control group 60.3 ± 15 years.

There is a statistically significant difference in pain intensity according to the WOMAC scale after the second dose of mesotherapy and one month after the fourth dose. WOMAC scores were significantly higher in patients in the control group (Table 1).

Similarly, there is a statistically significant difference in pain intensity according to the VAS scale after the second dose of mesotherapy and one month after the fourth dose. The frequency of patients experiencing moderate and severe pain was significantly higher in the control group, whereas the frequency of patients with no pain or mild

Table 1. Pain according to Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analogue scale (VAS) in experimental and control group

Parameters	Experimental group n (31)	Control group n (28)	p
WOMAC scale at the start of the study, median (range)	68 (28–90)	67 (34–96)	0.843
WOMAC scale after the second dose of mesotherapy, median (range)	33 (0–64)	55 (20–96)	< 0.001
WOMAC scale one month after the fourth dose of mesotherapy, median (range)	16 (0–64)	66 (26–96)	< 0.001
VAS scale at the start of the study, n (%)			
No pain	/	/	0.602
Mild pain	1 (3.2)	0 (0)	
Moderate pain	14 (45.2)	16 (57.1)	
Severe pain	16 (51.6)	12 (42.9)	
VAS scale after the second dose of mesotherapy, n (%)			
No pain	5 (16.1)	0 (0)	< 0.001
Mild pain	17 (54.8)	6 (21.4)	
Moderate pain	9 (29)	16 (57.1)	
Severe pain	0 (0)	6 (21.4)	
VAS scale one month after the fourth dose of mesotherapy, n (%)			
No pain	20 (64.5)	0 (0)	< 0.001
Mild pain	9 (29)	2 (7.1)	
Moderate pain	2 (6.5)	13 (46.4)	
Severe pain	0 (0)	13 (46.4)	

Table 2. Western Ontario and McMaster Universities Osteoarthritis Index scale in experimental group over time

Experimental group	n (31)	p
Start of the study, median (range)	68 (28–90)	< 0.001
After the second dose, median (range)	33 (0–64)	
After the fourth dose, median (range)	16 (0–64)	

Table 3. Western Ontario and McMaster Universities Osteoarthritis Index scale in control group over time

Control group	n (28)	p
Start of the study, median (range)	67 (34–96)	< 0.001
After the second dose, median (range)	55 (20–96)	
After the fourth dose, median (range)	66 (26–96)	

pain was significantly higher in the experimental group (Table 1).

There is a statistically significant difference in WOMAC scale values over time in patients in the experimental group. WOMAC scores decreased significantly over time (Table 2).

A statistically significant difference in WOMAC scale value over time was observed in patients in the control group. WOMAC scores decreased after the second dose, but increased again after the fourth dose (Table 3).

Also, a statistically significant difference was observed in the frequency of patients in the experimental group with varying pain intensity according to the VAS scale over time. The frequency of patients without pain increases over time. The frequency of patients with mild pain rises initially and then decreases, while the frequency of patients with moderate and severe pain decreases over time (Table 4).

Table 4. Visual analogue scale in experimental group over time

Experimental group	n (31)	p
Start of the study, n (%)		
No pain	/	
Mild pain	1 (3.2)	
Moderate pain	14 (45.2)	
Severe pain	16 (51.6)	< 0.001
After the second dose, n (%)		
No pain	5 (16.1)	
Mild pain	17 (54.8)	
Moderate pain	9 (29)	
Severe pain	/	
After the fourth dose, n (%)		
No pain	20 (64.5)	
Mild pain	9 (29)	
Moderate pain	2 (6.5)	
Severe pain	/	

Table 5. Visual analogue scale over time

Control group	n (28)	p
Start of the study, n (%)		
No pain	/	
Mild pain	/	
Moderate pain	16 (57.1)	
Severe pain	12 (42.9)	< 0.001
After the second dose, n (%)		
No pain	/	
Mild pain	6 (21.4)	
Moderate pain	16 (57.1)	
Severe pain	6 (21.4)	
After the fourth dose, n (%)		
No pain	/	
Mild pain	2 (7.1)	
Moderate pain	13 (46.4)	
Severe pain	13 (46.4)	

There is a statistically significant difference in the frequency of patients in the control group with varying pain intensity according to the VAS scale over time. The frequency of patients with mild pain rises initially and then decreases, while the frequency of patients with moderate pain stagnates then decreases, and the frequency of patients with severe pain decreases at first, but then increases over time (Table 5).

DISCUSSION

Mesotherapy is recognized as an effective alternative therapy for localized pain management [9], with studies demonstrating a reduction in neck and lower back pain by at least 50% compared to baseline levels [10]. In the context of acute conditions, Akbas et al. [11] observed that mesotherapy provides a statistically significantly greater reduction in pain intensity at 15 minutes, 30 minutes, and 24 hours post-treatment compared to intravenous dexamethasone administration. These findings are further supported by Costantino et al. [12], who suggested that mesotherapy, using a combination of lidocaine, ketoprofen, and methylprednisolone, represents a valid alternative to conventional systemic administration of NSAIDs and corticosteroids for acute low back pain. Furthermore, it has been shown that mesotherapy can achieve therapeutic effects equivalent to systemic drug administration [12], but with a significantly more favorable safety profile. Specifically, Chen et al. [13]

noted that mesotherapy resulted in fewer adverse effects, particularly regarding hemorrhage and WOMAC scores, when compared to traditional NSAID treatments.

The efficacy of this method extends to chronic syndromes as well. In patients with chronic lumbar syndrome and chronic thoracic spine pain, studies by Pires et al. [14] and Koszela et al. [15] both demonstrated that mesotherapy with type I collagen yields statistically significant improvements compared to lidocaine alone. Similarly, Ranieri et al. [16] reported reduced pain intensity and functional improvement in patients with bilateral cervicobrachial syndrome following a six-week treatment protocol.

In our study, the application of a Zodol (Hemofarm) and lidocaine mixture produced superior results in symptom reduction for knee osteoarthritis compared to lidocaine monotherapy. This aligns with the research by Tseveendorj et al. [17], who found that a combination of meloxicam and lidocaine significantly outperformed physiological saline,

with positive effects appearing within four weeks and lasting up to three months. These results are consistent with the conclusions of Farpour et al. [18], who identified piroxicam mesotherapy as an effective and safe procedure for patients with mild to moderate knee osteoarthritis. Collectively, these data underscore the clinical value of mesotherapy as a targeted, potent, and safe intervention for both spinal disorders and osteoarthritis-related pain.

CONCLUSION

The therapeutic effect of mesotherapy on pain in patients with knee osteoarthritis treated with a mixture of lidocaine and Zodol (Hemofarm) is more effective and longer-lasting compared to patients treated with lidocaine alone.

Conflict of interest: None declared.

REFERENCES

- Hsu H, Siwiec RM. Knee Arthroplasty (Archived). 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [PMID: 29939691]
- Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. *JAMA*. 2021;325(6):568–78. [DOI: 10.1001/jama.2020.22171] [PMID: 33560326]
- Mammucari M, Maggiori E, Russo D, Giorgio C, Ronconi G, Ferrara PE, et al. Mesotherapy: From Historical Notes to Scientific Evidence and Future Prospects. *ScientificWorldJournal*. 2020;2020:3542848. [DOI: 10.1155/2020/3542848] [PMID: 32577099]
- Fernanda H, Aparecida MM, Paulo FV. Mesotherapy: a bibliographical review. *An Bras Dermatol*. 2011;86(1):96–101. [DOI: 10.1590/s0365-05962011000100013]
- Brauneis S, Araimo F, Rossi M, Russo D, Mammucari M, Maggiori E, et al. The role of mesotherapy in the management of spinal pain. A randomized controlled study. *Clin Ter*. 2023;174(4):336–42. [DOI: 10.7417/CT.2023.2447] [PMID: 37378503]
- Mammucari M, Paolucci T, Russo D, Maggiori E, Di Marzo R, Migliore A, et al. A Call to Action by the Italian Mesotherapy Society on Scientific Research. *Drug Des Devel Ther*. 2021;15:3041–7. [DOI: 10.2147/DDDT.S321215] [PMID: 34285471]
- Bifarini B, Gori F, Russo D, Mammucari M, Maggiori E, Di Marzo R, et al. Intradermal therapy (mesotherapy): the lower the better. *Clin Ter*. 2022;173(1):79–83. [DOI: 10.7417/CT.2022.2396] [PMID: 35147651]
- Erümit Çamaş D, Öztürk O. Pain Mesotherapy Adventure of Three Sisters Who Applied to a Traditional And Complementary Medicine Center. *International Journal of Traditional and Complementary Medicine Research* 5 (3):199–203. [DOI: 10.53811/ijtcmr.1515240]
- Mammucari M, Maggiori E, Lazzari M, Natoli S. Should the General Practitioner Consider Mesotherapy (Intradermal Therapy) to Manage Localized Pain? *Pain Ther*. 2016;5(1):123–6. [DOI: 10.1007/s40122-016-0052-3] [PMID: 27229350]
- Mammucari M, Gatti A, Maggiori S, Sabato AF. Role of mesotherapy in musculoskeletal pain: opinions from the Italian society of mesotherapy. *Evid Based Complement Alternat Med*. 2012;2012:436959. [DOI: 10.1155/2012/436959] [PMID: 22654954]
- Akbas I, Kocak AO, Kocak MB, Cakir Z. Comparison of intradermal mesotherapy with systemic therapy in the treatment of low back pain: A prospective randomized study. *Am J Emerg Med*. 2020;38(7):1431–5. [DOI: 10.1016/j.ajem.2019.11.044] [PMID: 31859197]
- Costantino C, Marangio E, Coruzzi G. Mesotherapy versus Systemic Therapy in the Treatment of Acute Low Back Pain: A Randomized Trial. *Evid Based Complement Alternat Med*. 2011;2011:317183. [DOI: 10.1155/2011/317183] [PMID: 20953425]
- Chen L, Li D, Zhong J, Qiu B, Wu X. Therapeutic Effectiveness and Safety of Mesotherapy in Patients with Osteoarthritis of the Knee. *Evid Based Complement Alternat Med*. 2018;2018:6513049. [DOI: 10.1155/2018/6513049] Erratum in: *Evid Based Complement Alternat Med*. 2018;2018:5327589. [DOI: 10.1155/2018/5327589] [PMID: 29507592]
- Pires L, Santos N, Lana JV, de Macedo AP, Costa FR, Azzini GOM, et al. Upper Crossed Syndrome and Scapulae Upper-Trapping: A Mesotherapy Protocol in Cervicoscapulobrachial Pain-The 8:1 Block. *Bioengineering (Basel)*. 2024;11(11):1142. [DOI: 10.3390/bioengineering11111142] [PMID: 39593802]
- Koszela K, Woldańska-Okońska M, Skoczylas A, Słupiński M, Gasik R. Spinal collagen mesotherapy in patients with chronic thoracic back pain: a retrospective analysis of effectiveness and safety in a 3-month follow-up. *Reumatologia*. 2025;63(3):159–65. [DOI: 10.5114/reum/200192] [PMID: 40678029]
- Ranieri M, Marvulli R, D'Alesio E, Riccardi M, Raelle MV, Dell'Anna L, et al. Effects of Intradermal Therapy (Mesotherapy) on Bilateral Cervicobrachial Pain. *J Pers Med*. 2024;14(1):122. [DOI: 10.3390/jpm14010122] [PMID: 38276244]
- Tseveendorj N, Sindel D, Arman S, Sen EI. Efficacy of Mesotherapy for Pain, Function and Quality of Life in Patients with Mild and Moderate Knee Osteoarthritis: A Randomized Controlled Trial. *J Musculoskelet Neuronal Interact*. 2023;23(1):52–60. [PMID: 36856100]
- Farpour HR, Estakhri F, Zakeri M, Parvin R. Efficacy of Piroxicam Mesotherapy in Treatment of Knee Osteoarthritis: A Randomized Clinical Trial. *Evid Based Complement Alternat Med*. 2020;2020:6940741. [DOI: 10.1155/2020/6940741] [PMID: 32831875]

Терапијски ефекат мезотерапије бола код болесника са остеоартритисом колена

Маша Јакшић^{1,2}, Ивана Илић^{1,2}, Саша Милићевић^{1,2}, Душан Петровић^{1,2}, Саша Јовановић^{1,2}, Андријана Спасојевић¹, Наташа Мацут Ђукић², Лазар Попивоца¹, Никола Михајловић¹

¹Клиничко-болнички центар Косовска Митровица, Косовска Митровица, Србија;

²Универзитет у Приштини – Косовска Митровица, Медицински факултет, Косовска Митровица, Србија

САЖЕТАК

Увод/Циљ Остеоартритис колена представља дегенеративну, прогресивну болест зглоба колена која на крају може довести до инвалидитета. Клиничка мезотерапија представља интрадермалну терапију која се користи за убризгавање разблажених фармаколошких супстанци у површински слој коже у више тачака. Циљ истраживања био је да се утврди терапијски ефекат мезотерапије бола код болесника са остеоартритисом колена који су третирани мешавином Зодола (30 mg/mL, Хемофарм, Вршац, Србија) и лидокаина (лидокаин-хлорид 1%, 35 mg / 3,5 mL, Галеника, Београд, Србија), у односу на болеснике који су третирани само лидокаином.

Методе Студија је спроведена као проспективна. Учесници су насумично распоређени у две групе. Прву чини експериментална група у којој су болесници третирани инјекцијом која је садржала смешу лидокаина без адреналина и Зодола

(Хемофарм). Контролна група била је третирана раствором лидокаина, без адреналина.

Резултати Утврђена је статистички значајна разлика у интензитету бола после друге дозе мезотерапије и месец дана након четврте дозе мезотерапије. Вредности Индекса остеоартритиса универзитета Западни Онтарио и Мекмастер биле су значајно више код болесника у контролној групи. Удео болесника који осећају умерен и јак бол био је значајно већи у контролној групи, док је удео болесника без бола и са благим болом значајно већи у експерименталној групи.

Закључак Примена мезотерапије бола код болесника са остеоартритисом колена у експерименталној групи показала се ефикаснијом и дуготрајнијом у поређењу са применом само лидокаина.

Кључне речи: мезотерапија бола; остеоартритис колена; интрадермална терапија